Cargando…

A Case of Acquired Haemophilia A in a Patient with Chronic Myelomonocytic Leukaemia

A 67-year-old male, with a known diagnosis of myelodysplastic syndromes with multilineage dysplasia (MDS-MLD) was admitted to our hospital with a primary complaint of subcutaneous bleeding in his left thigh. Laboratory data showed anaemia and prolongation of activated partial thromboplastin time (85...

Descripción completa

Detalles Bibliográficos
Autores principales: Araki, Takeshi, Ohata, Shinya, Okamoto, Kohei, Morimoto, Kazuhide, Hiraishi, Mana, Yamada, Shinichiro, Mizuno, Ishikazu, Sugimoto, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6415290/
https://www.ncbi.nlm.nih.gov/pubmed/30937199
http://dx.doi.org/10.1155/2019/8612031
_version_ 1783403156971978752
author Araki, Takeshi
Ohata, Shinya
Okamoto, Kohei
Morimoto, Kazuhide
Hiraishi, Mana
Yamada, Shinichiro
Mizuno, Ishikazu
Sugimoto, Takeshi
author_facet Araki, Takeshi
Ohata, Shinya
Okamoto, Kohei
Morimoto, Kazuhide
Hiraishi, Mana
Yamada, Shinichiro
Mizuno, Ishikazu
Sugimoto, Takeshi
author_sort Araki, Takeshi
collection PubMed
description A 67-year-old male, with a known diagnosis of myelodysplastic syndromes with multilineage dysplasia (MDS-MLD) was admitted to our hospital with a primary complaint of subcutaneous bleeding in his left thigh. Laboratory data showed anaemia and prolongation of activated partial thromboplastin time (85.8 s, normal range 24–39 s) without thrombocytopenia. Coagulation factor VIII (FVIII) activity was less than 1% (normal range 60–150%), and a FVIII inhibitor was identified and quantified at 166 BU/mL to indicate a diagnosis of acquired haemophilia A (AHA). A recent, but sustained circulating monocytosis (>1 × 10(9)/L) was observed, which combined with elevated numbers of neutrophil and monocytic cells in the marrow, suggested evolution of MDS-MLD to chronic myelomonocytic leukaemia (CMML), coinciding with AHA. Further analysis revealed a karyotype of 46, XY, i(14) (q10), which was the same abnormality previously identified in the patient. To treat bleeding caused by AHA, steroid and activated prothrombin complex concentrate were administered. Azacitidine (AZA) was used to treat CMML. During the clinical course, bleeding partially improved; however, subsequent acute myocardial infarction occurred on day 87. Worsening bone marrow failure was observed 4 months after the original admission, despite administration of AZA therapy, and the patient died due to bleeding from AHA. This case suggests that the evolution of MDS to CMML status can be associated with AHA conferring a bleeding tendency.
format Online
Article
Text
id pubmed-6415290
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-64152902019-04-01 A Case of Acquired Haemophilia A in a Patient with Chronic Myelomonocytic Leukaemia Araki, Takeshi Ohata, Shinya Okamoto, Kohei Morimoto, Kazuhide Hiraishi, Mana Yamada, Shinichiro Mizuno, Ishikazu Sugimoto, Takeshi Case Rep Hematol Case Report A 67-year-old male, with a known diagnosis of myelodysplastic syndromes with multilineage dysplasia (MDS-MLD) was admitted to our hospital with a primary complaint of subcutaneous bleeding in his left thigh. Laboratory data showed anaemia and prolongation of activated partial thromboplastin time (85.8 s, normal range 24–39 s) without thrombocytopenia. Coagulation factor VIII (FVIII) activity was less than 1% (normal range 60–150%), and a FVIII inhibitor was identified and quantified at 166 BU/mL to indicate a diagnosis of acquired haemophilia A (AHA). A recent, but sustained circulating monocytosis (>1 × 10(9)/L) was observed, which combined with elevated numbers of neutrophil and monocytic cells in the marrow, suggested evolution of MDS-MLD to chronic myelomonocytic leukaemia (CMML), coinciding with AHA. Further analysis revealed a karyotype of 46, XY, i(14) (q10), which was the same abnormality previously identified in the patient. To treat bleeding caused by AHA, steroid and activated prothrombin complex concentrate were administered. Azacitidine (AZA) was used to treat CMML. During the clinical course, bleeding partially improved; however, subsequent acute myocardial infarction occurred on day 87. Worsening bone marrow failure was observed 4 months after the original admission, despite administration of AZA therapy, and the patient died due to bleeding from AHA. This case suggests that the evolution of MDS to CMML status can be associated with AHA conferring a bleeding tendency. Hindawi 2019-02-27 /pmc/articles/PMC6415290/ /pubmed/30937199 http://dx.doi.org/10.1155/2019/8612031 Text en Copyright © 2019 Takeshi Araki et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Araki, Takeshi
Ohata, Shinya
Okamoto, Kohei
Morimoto, Kazuhide
Hiraishi, Mana
Yamada, Shinichiro
Mizuno, Ishikazu
Sugimoto, Takeshi
A Case of Acquired Haemophilia A in a Patient with Chronic Myelomonocytic Leukaemia
title A Case of Acquired Haemophilia A in a Patient with Chronic Myelomonocytic Leukaemia
title_full A Case of Acquired Haemophilia A in a Patient with Chronic Myelomonocytic Leukaemia
title_fullStr A Case of Acquired Haemophilia A in a Patient with Chronic Myelomonocytic Leukaemia
title_full_unstemmed A Case of Acquired Haemophilia A in a Patient with Chronic Myelomonocytic Leukaemia
title_short A Case of Acquired Haemophilia A in a Patient with Chronic Myelomonocytic Leukaemia
title_sort case of acquired haemophilia a in a patient with chronic myelomonocytic leukaemia
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6415290/
https://www.ncbi.nlm.nih.gov/pubmed/30937199
http://dx.doi.org/10.1155/2019/8612031
work_keys_str_mv AT arakitakeshi acaseofacquiredhaemophiliaainapatientwithchronicmyelomonocyticleukaemia
AT ohatashinya acaseofacquiredhaemophiliaainapatientwithchronicmyelomonocyticleukaemia
AT okamotokohei acaseofacquiredhaemophiliaainapatientwithchronicmyelomonocyticleukaemia
AT morimotokazuhide acaseofacquiredhaemophiliaainapatientwithchronicmyelomonocyticleukaemia
AT hiraishimana acaseofacquiredhaemophiliaainapatientwithchronicmyelomonocyticleukaemia
AT yamadashinichiro acaseofacquiredhaemophiliaainapatientwithchronicmyelomonocyticleukaemia
AT mizunoishikazu acaseofacquiredhaemophiliaainapatientwithchronicmyelomonocyticleukaemia
AT sugimototakeshi acaseofacquiredhaemophiliaainapatientwithchronicmyelomonocyticleukaemia
AT arakitakeshi caseofacquiredhaemophiliaainapatientwithchronicmyelomonocyticleukaemia
AT ohatashinya caseofacquiredhaemophiliaainapatientwithchronicmyelomonocyticleukaemia
AT okamotokohei caseofacquiredhaemophiliaainapatientwithchronicmyelomonocyticleukaemia
AT morimotokazuhide caseofacquiredhaemophiliaainapatientwithchronicmyelomonocyticleukaemia
AT hiraishimana caseofacquiredhaemophiliaainapatientwithchronicmyelomonocyticleukaemia
AT yamadashinichiro caseofacquiredhaemophiliaainapatientwithchronicmyelomonocyticleukaemia
AT mizunoishikazu caseofacquiredhaemophiliaainapatientwithchronicmyelomonocyticleukaemia
AT sugimototakeshi caseofacquiredhaemophiliaainapatientwithchronicmyelomonocyticleukaemia